FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
← catalyst calendarNCT06564389 · readout in 286 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
119estimated
Sites
5
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-05 | actual | When the study began enrolling |
| Primary completion | 2027-06-02 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-06-02 | estimated | The whole study's end, after follow-up |
| First posted | 2024-08-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Healthy Participants
- Atopic Dermatitis
Interventions
- Drug: PF-07832837
- Other: Placebo
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs) and serious adverse events (SAEs) Following single ascending doses (SAD)
measured Baseline up to Day 35
Number of Participants with Clinically significant Laboratory Abnormalities Following SAD
measured Baseline up to Day 35
Number of Participants with Change from Baseline in Electrocardiogram (ECG) Findings Following SAD
measured Baseline up to Day 35
Number of Participants with Clinically Significant Change from Baseline in Vital Signs Following SAD
measured Baseline up to Day 35
Number of Participants with Clinically Significant Change from Baseline in Cardiac Telemetry Findings Following SAD
measured Day 1
Number of Participants With Treatment Emergent Treatment-Related AEs and SAEs Following multiple ascending doses (MAD)
measured Baseline up to Day 50
Number of Participants with Clinically significant Laboratory Abnormalities Following MAD
measured Baseline up to Day 50
Number of Participants with Change from Baseline in Electrocardiogram (ECG) Findings Following MAD
measured Baseline up to Day 50
Number of Participants With Treatment Emergent Treatment-Related AEs and SAEs in participants with atopic dermatitis (AD)
measured Baseline up to Day 80
Number of Participants with Clinically significant Laboratory Abnormalities in participants with AD
measured Baseline up to Day 80
Number of Participants with Clinically Significant Change from Baseline in Vital Signs in participants with AD
measured Baseline up to Day 78
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed